🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

The Genetic Mosaic of Depression: Linking Polymorphisms to Neuroplasticity and Stress Regulation.

PMID: 41754876 · DOI: 10.3390/ph19020336 · Pharmaceuticals (Basel, Switzerland), 2026 · Aneta Bednářová, Emma Szilassyová, Dominika Jarčušková, Daniel Múdry, Terézia Kisková-Šimková
📄 Abstract

The origins of major depressive disorder (MDD) are complex, involving both environmental influences and a substantial genetic contribution. Genetic polymorphisms have been implicated in modulating susceptibility, disease course, and treatment response, yet findings are often modest, population-dependent, and sometimes inconsistent. This narrative review synthesizes current evidence on genetic variants associated with MDD, highlighting well-replicated results while distinguishing exploratory or emerging findings. Key systems reviewed include serotonergic (

Confidence: 0.04 · 2 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Mechanism
0.00
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
0.00
In silico
0.00
Genetic association
The context describes genetic association studies for major depressive disorder (MDD), including polymorphisms in serotonergic system, MC4R gene variant (rs17782313), and GWAS-identified loci.
0.90
Ex vivo
0.00
Animal model
0.00
Diet/model
The context mentions a study on the interaction between MC4R gene variant and dominant dietary patterns on depression in obese and overweight women.
0.80
Клиника (11 полей)
Drug
0.00
Indication
0.00
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
0.00